Abbott, Medtronic, Boston Scientific Corporation ... the market is segmented based on product type (drug-eluting stent (DES), ...

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final two rounds ...

and will compare it to an historical control group of patients that have received drug-eluting stents through Medtronic’s prior clinical studies of its Resolute Onyx implant. Participants in ...

Hello Health Rounds Readers! Today we have three studies presented at medical meetings, including one testing a device that ...

Medtronic has received investigational device ... It will compare the Prevail DCB against drug-eluting stents using historical control data from the Resolute Onyx Clinical Program.

Results from the large-scale randomized ECLIPSE trial found that a lesion preparation strategy of routine orbital atherectomy had similar outcomes compared with conventional balloon angioplasty prior ...

Abbott, Boston Scientific, Medtronic, Biotronik ... Ranging from bare metal to drug-eluting stents, a more recent growing approach for bioresorbable and polymer-free stents is turning the market ...

To improve the management of coronary artery disease and lay the groundwork for future advancements in stent technology, ...

The 2024 edition of Transcatheter Cardiovascular Therapeutics (TCT) once again highlighted significant innovations in ...